Table S3 from Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations

Authors

Adib, Elio

Klonowska, Katarzyna

Giannikou, Krinio

Do, Khanh T.

15 more author(s)...

Description

Description from Figshare: "Table S3. Toxicities (any level) occurring in at least two patients, grouped by CTCAE v4.0 categories. For patients with more than one adverse event per category, only the highest-grade event was counted."

Subject

Clinical Trial, Phase II

Drug-Related Side Effects and Adverse Reactions

Everolimus

Neoplasms/drug therapy

TOR Serine-Threonine Kinases

Access Rights

Free to All